Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affymetrix Partners To Push Gene Chips Into Diagnostics Space

This article was originally published in The Gray Sheet

Executive Summary

Affymetrix, the inventors of genetic microarray technology used to explore the human genome in the 1990s, is leading the charge to apply the powerful research tool to human diagnostics

You may also be interested in...



With FDA’s Help, Firms Move Microarray-based Tests Into The Clinic

FDA and manufacturers are working together to come up with data analysis standards and other best practices to ensure that microarray-based technologies work consistently in real-world clinical settings

With FDA’s Help, Firms Move Microarray-based Tests Into The Clinic

FDA and manufacturers are working together to come up with data analysis standards and other best practices to ensure that microarray-based technologies work consistently in real-world clinical settings

People In Brief

Diagnostics and diabetes at Roche: Jürgen Schwiezer will take the helm of Roche's diagnostics business in January, the firm announces Oct. 2. He will succeed Severin Schwan, who will become CEO of the Swiss drug and diagnostic company in March (1"The Gray Sheet" July 23, 2007, p. 10). Schwiezer is Roche Diagnostic's president for Europe, Middle East and Africa, the unit's largest market region. Also on Oct. 2, Roche announced that Burkhard G. Piper, who heads the diabetes care division, will report directly to the company CEO beginning in January, rather than reporting to Schwiezer. Roche says it is not creating a separate diabetes business unit to join its pharmaceutical and diagnostic units, but the direct CEO report signals its intention to be more aggressive in the diabetes space, where it holds the number one worldwide position in blood glucose monitors (Accu-Chek) and number two in insulin infusion. Meanwhile, Roche is set to lose its top spot in the worldwide clinical laboratory diagnostics market with Siemens' imminent acquisition of Dade Behring (2"The Gray Sheet" July 30, 2007, p. 4)

Related Content

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel